From: Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
Treatment
Cost (CAD$)
Effect (QALYs)
Incremental Cost
Incremental Effect
ICER
BREN + AVD
$411,190
9.62
$192,336
0.46
$418,122
($300,490–$554,715)
(7.29–11.0)
ABVD
$218,854
9.16
($156,367–$310,743)
(6.98–10.49)